Advertisement

Topics

Companies Related to "Bacterial Efflux Pump Inhibitors Pipeline Insights 2017 Updated" [Most Relevant Company Matches] RSS

12:15 EDT 21st June 2018 | BioPortfolio

Here are the most relevant search results for "Bacterial Efflux Pump Inhibitors Pipeline Insights 2017 Updated" found in our extensive corporate database of over 50,000 company records.

Showing "Bacterial Efflux Pump Inhibitors Pipeline Insights 2017 Updated" Companies 1–25 of 1,700+

Extremely Relevant

Mpex Pharmaceuticals, Inc.

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacte...


Relevant

Tandem Diabetes Care®, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells the t:slim® Insulin Pump, the slimmest and smallest durable insulin pump current...

Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells the t:slim® Insulin Pump, the slimmest and smallest durable insulin pump current...


Entasis Therapeutics Inc.

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases. www.entasistx.com

KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can l...

RondinX

Founded in 2016 by leading microbiome experts, RondinX has built a cutting-edge microbiome technology platform set to unlock the potential of microbiome therapeutics. RondinX technology, including its PTR (Peak-to-Trough) family of algorithms, exclusively licensed from YEDA (the commercial arm of the Weizmann Institute of Science), is a proprietary, cloud-...

CircuLite

CircuLite® is transforming heart failure treatment with the development of minimally invasive devices for long-term partial circulatory support (PCS). By enabling a proactive and lower-risk treatment approach by supplementing a patient’s native pumping capacity, CircuLite has the potential to improve the quality of life for millions of chronic heart ...

Palleon Pharmaceuticals

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer...

PChemLabs Vacuum and Optical Instruments

PChemLabs Specializes in Used Vacuum Equipment Sales and ServiceUsed Vacuum Equipment, Rebuilt Vacuum Pumps, Used Mechanical Pumps, Rebuilt Mechanical Pumps, Used Vaccum Pumps, Vacuum Pump Repair, Vacuum Pump Service, Vacuum Pump Rebuilding, Custom Vacuum Chambers, Vacuum Pump Oil, Vacuum Fittings, Rebuilt Vacuum Pumps, Rebuilt Turbomolecular Pumps, Used Turbo Pumps, Used Ion Pump Controllers, Ion...

Amura Holdings Ltd

Amura has two complementary technology platforms which enable rapid and innovative drug discovery. AMcore™, the bicyclic core molecular scaffold chemistry and the computational screening and design platform, ProtoDiscovery™. Amura has four NCE discovery programmes based on AMcore™:An Osteoporosis programme based on cathepsin K inhibitors, A Psoriasis programme based on a cathepsin S inhibit...

Lupin Pharmaceuticals, Inc

Lupin is one of the world's largest manufacturers of drugs that combat tuberculosis,bacterial infections,and cardiovascular disease.Our portfolio of drugs, manufactured in global-scale USFDA and UKMCA approved plants,also includes NSAIDS,Cox2 inhibitors and herbal-based phytomedicines.

Proteolix, Inc.

Founded in December 2003, Proteolix, Inc. is a privately-held biotechnology company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. Prote...

Athelas SA

Athelas is a drug discovery company developing a novel class of drugs to treat bacterial infectious diseases. Contrary to conventional antibiotics, Athelas’ drugs treat bacterial infections by targeting mechanisms that are essential for bacterial colonization, invasion and survival only when bacteria are within the host’ environment. "

ILEX Oncology

Based in San Antonio, Texas, ILEX has a marketed product, Campath®, a treatment for patients with refractory chronic lymphocytic leukemia. ILEX is also advancing a robust pipeline of oncology product candidates. The pipeline comprises multiple technologies at all stages of clinical development, including a monoclonal antibody, apoptosis-inducing agents, cytotoxic compounds with novel mechanisms o...

FLX Bio, Inc.

FLX475 is a best-in-class oral, small molecule antagonist of CCR4. CCR4 ligands are elevated in multiple tumor types when compared to normal tissue. In preclinical studies, FLX475 inhibited tumor growth and increased tumor regression. In addition, FLX475 enhanced the antitumor effects of various checkpoint inhibitors including anti-PD-L1 and anti-CTLA4 ant...

Discuva

Discuva aims to revolutionise the treatment of disease caused by bacterial infection by discovering and developing new antibiotics against highly drug-resistant pathogens. The company’s innovative proprietary technologies both identify new small molecule drugs against novel bacterial targets and facilitate their progression through to drug candidates ...

Ayala Pharmaceuticals

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. The company was founded in November 2017 with an experienced global management team and a strong investor base. The management bench recently expanded with the appointment of Andrea Vergar...

Barnant

Barnant is known worldwide as a leading manufacturer of peristaltic pump technology; as the manufacturer of the highly regarded Masterflex® peristaltic pump line; and as a world-class innovator in the engineering, design, manufacturing and distribution of an extensive line of fluid handling and flow control products. This includes the other well-known brands

Procarta Biosystems

Procarta Biosystems is developing a new class of DNA-based therapeuticals, snare™ antibacterials, capable of combating drug-resistant bacterial infections. snare™ antibacterials act on novel genomic targets by capturing key regulatory proteins to block essential bacterial genes and defeat infection. Procarta is creating an extensive pipeline to tackle some of the most challenging b...

NAM Asia Hong Kong Co., Ltd.

CEO Teppei Nakano graduated from Keio University School of Medicine in 2017. We have been adopting IPA unexplored projects by the Ministry of Economy, Trade and Industry, which represent a large number of representatives of IT companies representing Japan, twice in 2016 and 2017, independent businesses that have been adopted by unexplored This is the NAM p...

QIAGEN GmbH

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these...

Capitol Insights

Capitol Insights helps organizations develop and implement comprehensive public relations and government affairs programs to educate the public, motivate people and shape public policy.Capitol Insights helps clients understand how policy may move in the future because of changes in public opinion, political pressure and legal interpretation. Helping organizations make better decisions and build st...

IBIS Technologies BV

The IBIS iSPR is a novel imaging SPR instrument that allows the simultaneous monitoring of multiple binding interactions to the surface of one and the same sensor. This way, it can be used for real-time detection of the possible binding events to the many spots of a micoarray, for example. Thanks to it flexibility, the instrument can also be accomodated to be used as a, more conventionel, 1- and 2...

Isarna Therapeutics GmbH

Isarna Therapeutics has an unmatched commitment to developing TGF-β inhibitors that stimulate the human immune system to effectively fight cancer. Isarna Therapeutics are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.  The role of tgf-beta in cancer The cytokine human transforming growth ...

Macrolide Pharmaceuticals

Macrolide Pharmaceuticals focuses on the discovery and development of novel macrolide antibiotics for the treatment of life-threatening bacterial infections caused by drug resistant pathogens. Using novel technology, Macrolide Pharmaceuticals can synthesize a broad range of macrolides, and initial compounds show promising anti-bacterial activity. The compa...


More From BioPortfolio on "Bacterial Efflux Pump Inhibitors Pipeline Insights 2017 Updated"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks